ABIVAX Société Anonyme Company Description

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body’s natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases.

The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.

ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.

ABIVAX Société Anonyme

Country	France
Founded	2013
Industry	Medical - Pharmaceuticals
Sector	Healthcare
Employees	61
CEO	Marc M. de Garidel

Contact Details

Address: 7-11 boulevard Haussmann Paris, 75009 France
Phone	33 1 53 83 09 63
Website	abivax.com

Stock Details

Ticker Symbol	0RA9
Exchange	London Stock Exchange
Stock Type	Common Stock
Fiscal Year	January - December
Reporting Currency	EUR
ISIN Number	FR0012333284
SIC Code	2836

Key Executives

Name	Position
Didier Blondel	EVice President, Chief Financial Officer and Board Secretary
Didier Scherrer Ph.D.	Chief Scientific Officer
Patrick Malloy	Senior Vice President of Investor Relations
Ida Hatoum	Chief People and Compliance Officer
Pierre Courteille M.B.A.	Chief Business Officer
Jerome Denis Ph.D.	Executive Vice President of Process Development and Manufacturing
Ana Sharma M.P.H.	Vice President and Global Head of Quality
Hema Keshava	Senior Vice President of Finance
Chris Rabbat Ph.D.	Vice President and Global Head of Medical Affairs
Kevin Shan Ph.D.	Vice President and Global Head of Biometrics